Abbott falls on plant QSR (US quality system regulation) failure
This article was originally published in Clinica
Shares in Abbott Laboratories dropped by over 9% last week on the release of an FDA report that found that its Lake County, Illinois, diagnostic plant still failed to meet US quality system regulation (QSR) standards. The plant, which produces lab and hospital blood tests among a range of 400 medical products, had been visited in January 2002 (see Clinica No 994, p 15). This followed an FDA consent decree in 1999, in which Abbott was fined $100 million and had a slew of products removed from the market (see Clinica No 883, p 1).
You may also be interested in...
Sandoz Canada has become the first manufacturer to launch generic versions of posaconazole and silodosin in Canada. The company launched the generic version of Allergan’s Rapaflo (silodosin) after a Canadian court ruled that Sandoz did not infringe a key formulation patent.
US healthcare insurance provider Health Net failed to respect Amarin’s patent rights in the way it distributed Hikma’s generic version of Vascepa (icosapent ethyl), the originator contends in an expanded induced infringement suit.
Netherlands' Authority for Consumers and Markets has reprimanded a dietary supplements player for purchasing fake followers and likes on social media to exaggerate the popularity of its products. It is the first case of its kind in the country.